Bicalutamide

For research use only.

Catalog No.S1190 Synonyms: ICI-176334

22 publications

Bicalutamide Chemical Structure

Molecular Weight(MW): 430.37

Bicalutamide is an androgen receptor (AR) antagonist with IC50 of 0.16 μM in LNCaP/AR(cs)cell line. Bicalutamide promotes autophagy.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 109 In stock
USD 120 In stock
USD 210 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Bicalutamide has been cited by 22 publications

Purity & Quality Control

Choose Selective Androgen Receptor Inhibitors

Biological Activity

Description Bicalutamide is an androgen receptor (AR) antagonist with IC50 of 0.16 μM in LNCaP/AR(cs)cell line. Bicalutamide promotes autophagy.
Targets
Androgen Receptor [1]
(LNCaP/AR(cs) cells)
0.16 μM
In vitro

Bicalutamide undergoes an antagonist-to-agonist switch, stimulating AR activity. Bicalutamide treatment of LNCaP/AR(cs) cells in absence of the synthetic androgen R1881 results in altered gene expression consistent with its well-documented agonist activity in context of AR overexpression. Bicalutamide induces cell proliferation in a dose-dependent manner, and only partially antagonized the effects of R1881. Bicalutamide treatment also results in a significant amount of nuclear AR, although less than that observed with R1881. Bicalutamide exhibits partial agonist activity as evidenced by induction of DNA binding at AR target genes and incomplete antagonism of the effects of R1881. In absence of R1881, Bicalutamide partially activates VP16-AR–mediated transcription, indicative of AR binding to DNA. In LNCaP/AR-luc cells with a stably integrates AR-driven luciferase reporter construct. In the presence of R1881, Bicalutamide shows only weak partial antagonism of VP16-AR–mediated transcription with an IC50 of 0.35 μM. [1] Micromolar bicalutamide causes a significant dose-dependent reduction in clonogenicity. [2] Dual inhibition of the AR and mTOR signaling pathways provides further benefit with the ridaforolimus-bicalutamide combination producing syner -gistic antiproliferative effects in prostate cancer cells in vitro when compared with each agent alone. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MDA-MB-453 cells M4Phb2Z2dmO2aX;uJIF{e2G7 M1\2eGRqe3CuYXPlcYVvfCCxZjDbN2heWjF6OEGg[pJwdSCDUjDpckBpfW2jbjDNSGEuVUJvNEWzJINmdGy|LDDFR|UxRTNzIH7N NI\KfW8zOzdzM{W2Oy=>
LNCaP cells NVvJc5VrTnWwY4Tpc44h[XO|YYm= NInpRmRKdmirYnn0bY9vKG:oIGuzTH0uTEiWIHLpcoRqdmdidH:gWFg4P0FiYX7kdo9o\W5icnXj[ZB1d3Jib3[gUG5E[VBiY3XscJMtKEurPUO1JI5O M2jHT|E2PjB|OU[w
Freestyle293F cells NGf6blhHfW6ldHnvckBie3OjeR?= NHrIeFZKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDBcoRzd2enbjDy[YNmeHSxcjCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBHemWnc4T5cIUzQTOIIHPlcIx{NCCLQ{WwQVAvODV2IN88US=> M3r0V|I{OTl7NEe3
HEK293 cells M1m3UWZ2dmO2aX;uJIF{e2G7 MlHLN{Bp NEHhXZNFcXOybHHj[Y1mdnRib3[gX|E4NWGucHjhMY1mfGi7bD2zTH1ucWKxbHXyc45mKG[{b32gZY5lem:pZX6gdoVk\XC2b4Kg[ZhxemW|c3XkJIlvKEiHS{K5N{Bk\WyuczDh[pRmeiB|IHjyd{whUUN3ME21OEBvVQ>? M1y2VFIzOzlzMEOz
MDA453 cells MVvGeY5kfGmxbjDhd5NigQ>? NInJSWRFcXOybHHj[Y1mdnRib3[gX|NJZUSKVDDmdo9uKGi3bXHuJIFv\HKxZ3XuJJJm[2WydH;yJIlvKE2GQUS1N{Bk\WyuczygT4k:PjRibl2= MkHVNVgzQTF4NES=
human MDA-MB-453 cells M2DucmZ2dmO2aX;uJIF{e2G7 M1;wXGRqe3CuYXPlcYVvfCCxZjDbN2heTEiWIH\yc40hSVJiaX6gbJVu[W5iTVTBMW1DNTR3MzDj[YxteyxiSVO1NF03PCCwTR?= MUOyNFU5PDZzMB?=
COS1 cells MYnGeY5kfGmxbjDhd5NigQ>? NFHjfXJCdnSjZ3;ubZN1KGGldHn2bZR6KGGpYXnud5QheFOJNT30ZYdo\WRiaIXtZY4h[W6mcn;n[Y4hemWlZYD0c5Ih\XiycnXzd4VlKGmwIFPPV|Eh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIILlZ4VxfG:{LX3l[IlifGWmIITyZY5{[3KrcITpc45idCCjY4Tpeol1gSCkeTDBVk1z\We3bHH0[YQhemG2IIDyc4Jie2mwIIDyc41wfGW{IH\yZYdu\W62IHTybZZmdiCoaYLl[ox6KGy3Y3nm[ZJie2VicnXwc5J1\XJiYYPzZZktKEmFNUC9NE4xQDZ7IN88US=> NXHYSVhSOjV4NE[2OFk>
HeLa cells MWTGeY5kfGmxbjDhd5NigQ>? Mn62RY51[WexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBidmS{b3flckBz\WOncITvdkBmgHC{ZYPz[YQhcW5iSHXMZUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHTpbJllem:2ZYP0c5N1\XKxbnWgbY5lfWOnZDD0doFve2O{aYD0bY9v[WxiYXP0bZZqfHliYomgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhUUN3ME2wMlE1KM7:TR?= MoD4NVc5ODR{Mkm=
CV1 cells MWPGeY5kfGmxbjDhd5NigQ>? M13GN2JqdmSrbnegZYZncW6rdImgeI8hcHWvYX6gZY5lem:pZX6gdoVk\XC2b4Kg[ZhxemW|c3XkJIlvKEOYMTDj[YxteyxiS3m9NE4yPTFizszN NV;IdZR[OTd{NUe4N|g>
monkey COS7 cells NXG2U5JWTnWwY4Tpc44h[XO|YYm= MlTHRolv\GmwZzDh[oZqdmm2eTD0c{BpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hdW:wa3X5JGNQWzdiY3XscJMh[nlid3jvcIUh[2WubDDibY5lcW6pIHHzd4F6NCCNaU2wMlE2OSEQvF2= NVniSpUyOTh2NEK5NVI>
COS7 cells NGHCWFJHfW6ldHnvckBie3OjeR?= MknBRYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDXO|QySyCvdYThcpQh\XiycnXzd4VlKGmwIFPPV|ch[2WubIOgZZN{\XO|ZXSgZZMhdHWlaX\ldoF{\SCjY4Tpeol1gSCjZoTldkAzPCCqcoOgZpkhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NF0xNjF6IN88US=> MoLJNlIxQTR{N{m=
CHO-K1 cells NGHXbZpHfW6ldHnvckBie3OjeR?= MYCyJIg> NX\2S45GTGm|cHzhZ4Vu\W62IH;mJHs{UF2vaXLvcIVzd26nIH\yc40hcHWvYX6gRXIh\XiycnXzd4VlKGmwIFPIU{1MOSClZXzsd{Bi\nSncjCyJIhzeyCkeTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oNCCLQ{WwQVAvOiEQvF2= MUOyNFM5OTN4MR?=
human HT-3 cell NHzqVHRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWXvfWJbUW6qaXLpeIlwdiCxZjDoeY1idiCKVD2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44OzF|NDFOwG0> NG\lc4hUSU6JRWK=
human LNCAP cells MlP5VJJwdGmoZYLheIlwdiCjc4PhfS=> MYmzJIRigXN? NIrIN|lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFzOR2FRKGOnbHzzJIFnfGW{IEOg[IF6eyxiSVO1NF0xNjd|Mkeg{txO MmTLNlYxPDZ|MUO=
human PC3 cells NHfOcmZHfW6ldHnvckBie3OjeR?= Mo\wSIl{eGyjY3Xt[Y51KG:oIGuzTH1TOTh6MTDmdo9uKGGwZILv[4VvKHKnY3XweI9zKGmwIHj1cYFvKFCFMzDj[YxteyxiRVO1NF01NjNizszN MlXyNlU2QTFyNk[=
human 22Rv1 cells Ml3wSpVv[3Srb36gZZN{[Xl? NELkXmc{KGSjeYO= NU\ycW11SW62YXfvcol{fCCjY4Tpeol1gSCjdDDhcoRzd2enbjDy[YNmeHSxcjDIPFc1YSCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iaIXtZY4hOjKUdkGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCGSGStbY5lfWOnZDDj[YxtKGe{b4f0bEBi\nSncjCzJIRigXNiYomgW3NVNThiYYPzZZktKEmFNUC9OE43KM7:TR?= Mn3SNlQ6ODB3OEi=
human CCF-STTG1 cell MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHzUNI9KdmirYnn0bY9vKG:oIHj1cYFvKEOFRj3TWHRIOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G778{MJGlEPTB;ND65NlkzQSEQvF2= M3Lve3NCVkeHUh?=
human SCC-25 cell NYe4[Gd7T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NY\qeVNGUW6qaXLpeIlwdiCxZjDoeY1idiCVQ1OtNlUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjB6NkW2JO69VQ>? NEXETGlUSU6JRWK=
human MKN45 cell M{SxNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIXNU4FKdmirYnn0bY9vKG:oIHj1cYFvKE2NTkS1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok46PjB3IN88US=> MYLTRW5ITVJ?
human ES5 cell MlnDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYDTcZI1UW6qaXLpeIlwdiCxZjDoeY1idiCHU{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlYyOTV2IN88US=> M{LDRnNCVkeHUh?=
human SK-MEL-3 cell M{SxS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF7sbpFKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTBwMEm2OEDPxE1? M3zoPHNCVkeHUh?=
human PC-3 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWnJcohq[mm2aX;uJI9nKGi3bXHuJHBENTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMD6yO|kyKM7:TR?= MnHlV2FPT0WU
human NOS-1 cell M4Xqfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH[2bFhKdmirYnn0bY9vKG:oIHj1cYFvKE6RUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVEvOjlzNzFOwG0> MYHTRW5ITVJ?
human LB1047-RCC cell NYKwbY1[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2TPdmlvcGmkaYTpc44hd2ZiaIXtZY4hVEJzMES3MXJESyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF{LkK1N{DPxE1? NX7iW2p2W0GQR1XS
human CAMA-1 cell MkfuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkCzTY5pcWKrdHnvckBw\iCqdX3hckBESU2DLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNk4{QTJ4IN88US=> MW\TRW5ITVJ?
human SAS cell M{nTNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmHCTY5pcWKrdHnvckBw\iCqdX3hckBUSVNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMz6zNFgyKM7:TR?= M1jCTnNCVkeHUh?=
human NCI-H2228 cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnfWTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKyNlgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOy55NUOxJO69VQ>? NULkcZBGW0GQR1XS
human NCI-H187 cell NYGzeplpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHjJeHJKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVg4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTZwNk[xOkDPxE1? NITxVYNUSU6JRWK=
human BFTC-905 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXfJcohq[mm2aX;uJI9nKGi3bXHuJGJHXENvOUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVcvPDh3NzFOwG0> MnnaV2FPT0WU
human G-361 cell M2S3bWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF3JS4RKdmirYnn0bY9vKG:oIHj1cYFvKEdvM{[xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVcvQDJ4IN88US=> NX7CNFFNW0GQR1XS
human DU145 cells M1zSPWN6fG:2b4jpZ:Kh[XO|YYm= M4fiRlczKGh? NILkNoREgXSxdH;4bYNqfHliYXfhbY5{fCCHUnHsdIhiNWSnZnnjbYVvfCCqdX3hckBFXTF2NTDj[YxteyCneIDy[ZN{cW6pIFXSZoV1[SCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTF6IN88US=> NV\qd2Y6W0GQR1XS
human SW780 cell Mn3IS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2TMXWlvcGmkaYTpc44hd2ZiaIXtZY4hW1d5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfS=> Ml\uV2FPT0WU
human BB49-HNC cell NGnzTI5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoDrTY5pcWKrdHnvckBw\iCqdX3hckBDSjR7LVjOR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE5Njl3M{Kg{txO MXLTRW5ITVJ?
human KALS-1 cell M4XFNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYnJcohq[mm2aX;uJI9nKGi3bXHuJGtCVFNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG5MlY3OzVizszN MUfTRW5ITVJ?
human AU565 cell NI\HN4xIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIj5fnZKdmirYnn0bY9vKG:oIHj1cYFvKEGXNU[1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVkvPzRyMjFOwG0> M2jpR3NCVkeHUh?=
human NCI-H2087 cell NGnTfGtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV7Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkC4O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIyNjB3OUGg{txO NVnsfINiW0GQR1XS
human RVH-421 cell MlTDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mmq1TY5pcWKrdHnvckBw\iCqdX3hckBTXkhvNEKxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlEvPTd7NTFOwG0> M1qzb3NCVkeHUh?=
human SK-CO-1 cell MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkXUTY5pcWKrdHnvckBw\iCqdX3hckBUUy2FTz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlEvQDh5MjFOwG0> NHH5VHhUSU6JRWK=
human KU-19-19 cell NYjLZmdqT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXjJcohq[mm2aX;uJI9nKGi3bXHuJGtWNTF7LUG5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlIvODJ2MjFOwG0> MU\TRW5ITVJ?
human NB6 cell M1PUNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3TifmlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkKuPVE{PSEQvF2= M1HlR3NCVkeHUh?=
human RO82-W-1 cell NVPMZlF[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmnITY5pcWKrdHnvckBw\iCqdX3hckBTVzh{LWetNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI{NjF|MUig{txO M4m0U3NCVkeHUh?=
human LNCAP cells MkezR5l1d3SxeHnjxsBie3OjeR?= NHvQ[nEzKGSjeYO= MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMUmNCWCClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjCyJIRigXNiYomgZ4VtdCClb4XueIlv\yCvZYToc4QtKEmFNUC9NlMvPzlizszN MX[yN|czPzB2NB?=
human CTB-1 cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3jJO2lvcGmkaYTpc44hd2ZiaIXtZY4hS1SELUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yOE42PTN4IN88US=> NV[xZXpDW0GQR1XS
human SW48 cell MoTFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVrJcohq[mm2aX;uJI9nKGi3bXHuJHNYPDhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{ND62OVQ3KM7:TR?= M3L6XnNCVkeHUh?=
human TCCSUP cell NHTZU5RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M33mXGlvcGmkaYTpc44hd2ZiaIXtZY4hXEOFU2XQJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlQvPzJ|MjFOwG0> MXPTRW5ITVJ?
human DK-MG cell MnvRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGRMNU2JIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkSuPFkyPyEQvF2= NIL0eVhUSU6JRWK=
human ST486 cell MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGrTV5lKdmirYnn0bY9vKG:oIHj1cYFvKFOWNEi2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlUvPzR4NDFOwG0> M{XyUnNCVkeHUh?=
human H4 cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIO3ZWdKdmirYnn0bY9vKG:oIHj1cYFvKEh2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mk[uPVQ2QCEQvF2= MmDkV2FPT0WU
human SBC-1 cell NGLNbVhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFXjcG9KdmirYnn0bY9vKG:oIHj1cYFvKFOEQz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlgvOzVyNzFOwG0> Mk\xV2FPT0WU
human CAS-1 cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{nyVWlvcGmkaYTpc44hd2ZiaIXtZY4hS0GVLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yPE43Ojl2IN88US=> NVXH[FM2W0GQR1XS
human OAW-42 cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1\SNGlvcGmkaYTpc44hd2ZiaIXtZY4hV0GZLUSyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlgvPzF7NTFOwG0> NUix[VNyW0GQR1XS
human HCC1954 cell NUnhZ4VpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXXJcohq[mm2aX;uJI9nKGi3bXHuJGhESzF7NUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yPE44PTJ3IN88US=> M3njc3NCVkeHUh?=
human MDA-MB-453 cell M4O5PGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXLPXoVDUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuPDV|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkmuPVA4KM7:TR?= MVPTRW5ITVJ?
human MCF7 cell MonHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1q2[mlvcGmkaYTpc44hd2ZiaIXtZY4hVUOINzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUO5MlMxOSEQvF2= MXvTRW5ITVJ?
human PC3 cells NUTnc3dnTnWwY4Tpc44h[XO|YYm= MnT5NVAx64DCzszN NFq0OWU1QCCq M1u3ZmlvcGmkaYTpc44hd2ZiYXP0bY4h[mG|ZXSgdJNmfWSxcH;kbYEh\m:{bXH0bY9vKGmwIHHu[JJw\2WwLXTldIVv\GWwdDDoeY1idiCSQ{OgZ4VtdHNiYYSgNVAxKHWPIHHmeIVzKDR6IHjyd{BjgSCGQWDJJJN1[WmwaX7nJIJie2WmIH\seY9z\XOlZX7j[UBucWO{b4Pjc5B6KGG|c3H5 MXGyNlY4Ojl6NB?=
human PC3 cells NIX1enJHfW6ldHnvckBie3OjeR?= NHvJPGExNjFvMTFOwG0> NWf4NFdTSWexbnnzeEBi[3Srdnn0fUBifCCjbnTyc4dmdiC{ZXPldJRweiCZN{SxR{BufXSjboSg[ZhxemW|c3XkJIlvKGi3bXHuJHBEOyClZXzsd{Bie3Onc4Pl[EBieyC|dHnteYxifGmxbjDv[kBz\WOncITvdkB1emGwc3HjeIl3[XSrb36gZZQhOC5zIITvJFEhfU1iYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6 NG\FO2ozOjF5NU[5OC=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Cytosolic AR / Nuclear AR ; 

PubMed: 30833616     


The representative expressions and the quantifications of proteins regarding the bicalutamide-induced apoptosis. (a) downregulation of nuclear androgen receptor (nAR).

30833616
Growth inhibition assay
Cell viability; 

PubMed: 27994514     


MDA-MB-231 and HCC1937 cells were treated with 10 μM bicalutamide and 10μM ABT-888 alone or in combination for 24h, 48h, 72h, and cell viability was determined by MTT assay.

27994514
In vivo Single bicalutamide reduces tumor growth by 79%, at defined submaximal doses. The ridaforolimus-bicalutamide combination exhibits improved and potent antitumor activity, almost completely abrogating tumor growth. The combination is also well tolerated, as evidenced by no significant changes in body weight over the course of treatment. Plasma PSA levels are again tightly linked to tumor growth in the combination-treated mice. [3]

Protocol

Kinase Assay:[1]
- Collapse

Whole-cell competitive binding assays:

Whole-cell competitive binding assays are performed in LNCaP/AR(codon-switch) (LNCaP/AR(cs)) (harbors a mixture of exogenous wild-type AR and endogenous mutant AR (T877A)) and cells propagated in Iscove's or RPMI media supplemented with 10% fetal bovine serum, or during the assay with 10% charcoal-stripped, dextran-treated fetal bovine serum (CSS). Cells are pre-incubated with 18F-FDHT, increasing concentrations (1pM to 1μM) of cold Bicalutamide are added, and the assay is performed to measure specific uptake of 18F-FDHT (4). IC50 values are determined using a one site binding model with least squares curve fitting and R2 > 0.99.
Cell Research:[3]
- Collapse
  • Cell lines: C4-2 cell
  • Concentrations: 0-1 μM
  • Incubation Time: 72 hours
  • Method: Exponentially growing C4-2 cells are plated into two 96-well plates and incubated overnight at 37 ˚C. Twenty-four hours later one plate is aspirated and stored at -80 ˚C and the other treated with 10-fold serial concentrations of ridaforolimus (1000 nM to 0.0001 nM) or vehicle (ethanol). Following 72 hours culture at 37 ˚C, the plates are assessed simultaneously for cell growth using the Cy qUANT Cell Proliferation Assay kit. Bicalutamide and Ridaforolimus combination proliferation assays are performed similarly except cell growth is determined as the change in cell number between vehicle control and compound treated cells after 72 hours in culture.
    (Only for Reference)
Animal Research:[3]
- Collapse
  • Animal Models: Male nude mice bearing C4-2 cells
  • Dosages: 10 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL (199.82 mM)
Water Insoluble
Ethanol '5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 430.37
Formula

C18H14F4N2O4S

CAS No. 90357-06-5
Storage powder
in solvent
Synonyms ICI-176334
Smiles CC(O)(C[S](=O)(=O)C1=CC=C(F)C=C1)C(=O)NC2=CC=C(C#N)C(=C2)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02910050 Unknown status Drug: Bicalutamide|Drug: Aromatase Inhibitor Breast Cancer Xu fei|Sun Yat-sen University January 2016 Phase 2
NCT02614859 Recruiting Drug: Bicalutamide|Drug: Metformin and Bicalutamide Cancer of Prostate Fox Chase Cancer Center|National Cancer Institute (NCI) December 1 2015 Phase 2
NCT02146937 Withdrawn Drug: Bicalutamide plus Finasteride- Combination therapy Detectable Prostate Nodules Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins March 2014 Phase 2
NCT01415791 Completed Drug: ICI176334-1 Healthy AstraZeneca August 2011 Phase 1
NCT01415778 Completed Drug: ICI176334-1|Drug: Casodex 80 mg tablet Healthy AstraZeneca August 2011 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Androgen Receptor Signaling Pathway Map

Related Androgen Receptor Products

Tags: buy Bicalutamide | Bicalutamide ic50 | Bicalutamide price | Bicalutamide cost | Bicalutamide solubility dmso | Bicalutamide purchase | Bicalutamide manufacturer | Bicalutamide research buy | Bicalutamide order | Bicalutamide mouse | Bicalutamide chemical structure | Bicalutamide mw | Bicalutamide molecular weight | Bicalutamide datasheet | Bicalutamide supplier | Bicalutamide in vitro | Bicalutamide cell line | Bicalutamide concentration | Bicalutamide nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID